[{"id":"1ff054af-6a2d-443b-a5c7-8c8c9ac57674","acronym":"","url":"https://clinicaltrials.gov/study/NCT01280552","created_at":"2021-07-10T10:52:43.565Z","updated_at":"2024-07-02T16:37:24.317Z","phase":"Phase 2b","brief_title":"A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)","source_id_and_acronym":"NCT01280552","lead_sponsor":"Precision Life Sciences Group","biomarkers":" MGMT","pipe":" | ","alterations":" HLA-A2 positive","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ICT-107"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2017-03-20"}]